Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies

The Microbiome Disease Pipeline Report 2025 reveals 180+ drugs under development across 140+ companies, covering late-stage, mid-stage, and early-stage therapies. Major players such as MaaT Pharma, Seres Therapeutics, Biomica, and Vedanta Resources Biosciences are advancing Phase III and II candidates targeting microbiome-related conditions. The report offers detailed drug profiles, clinical trial insights, therapeutic assessments, and emerging trends shaping the future of microbiome-based therapeutics.

Dublin, March 21, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Disease - Pipeline Insight, 2025" drug pipeline report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Microbiome Disease R&D. The therapies under development are focused on novel approaches to treat/improve Microbiome Disease.

Microbiome Disease Emerging Drugs Chapters

This segment of the Microbiome Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Microbiome Disease Emerging Drugs

• MaaT 013: MaaT Pharma
• QBKPN: Qu Biologics
• BMC128: Biomica Ltd.
• SER-155: Seres Therapeutics
• MVT-201: Micro Viable Therapeutics

Microbiome Disease: Therapeutic Assessment

This segment of the report provides insights about the different Microbiome Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Microbiome Disease

There are approx. 140+ key companies which are developing the therapies for Microbiome Disease. The companies which have their Microbiome Disease drug candidates in the most advanced stage, i.e. Phase III include, MaaT Pharma

The report covers around 180+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Microbiome Disease Report Insights

• Microbiome Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Microbiome Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• MaaT Pharma
• Qu Biologics
• Biomica Ltd.
• Seres Therapeutics
• Micro Viable Therapeutics
• Metagen Therapeutics, Inc
• Microbiotica
• Enterome
• Azitra
• Vedanta Resources Biosciences, Inc

Key Products

• MaaT 013
• QBKPN
• BMC128
• SER-155
• MVT-201
• MaaT03X
• MGT-001
• MGT-007
• MB097
• MB310
• EO2463
• ATR-12
• ATR-04
• VE202
• VE303
• VE707

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dv1unu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900